71 related articles for article (PubMed ID: 10342561)
1. The molecular perspective: p53 tumor suppressor.
Goodsell DS
Stem Cells; 1999; 17(3):189-90. PubMed ID: 10342561
[No Abstract] [Full Text] [Related]
2. The molecular perspective: p53 tumor suppressor.
Goodsell DS
Oncologist; 1999; 4(2):138-9. PubMed ID: 10337384
[No Abstract] [Full Text] [Related]
3. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
4. Structure of the human p53 core domain in the absence of DNA.
Wang Y; Rosengarth A; Luecke H
Acta Crystallogr D Biol Crystallogr; 2007 Mar; 63(Pt 3):276-81. PubMed ID: 17327663
[TBL] [Abstract][Full Text] [Related]
5. Modeling the interaction between the N-terminal domain of the tumor suppressor p53 and azurin.
Taranta M; Bizzarri AR; Cannistraro S
J Mol Recognit; 2009; 22(3):215-22. PubMed ID: 19140135
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen MG; Slootweg PJ
Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
[TBL] [Abstract][Full Text] [Related]
8. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
[TBL] [Abstract][Full Text] [Related]
9. p53--a natural cancer killer: structural insights and therapeutic concepts.
Römer L; Klein C; Dehner A; Kessler H; Buchner J
Angew Chem Int Ed Engl; 2006 Oct; 45(39):6440-60. PubMed ID: 16983711
[TBL] [Abstract][Full Text] [Related]
10. The role of tetramerization in p53 function.
Chène P
Oncogene; 2001 May; 20(21):2611-7. PubMed ID: 11420672
[TBL] [Abstract][Full Text] [Related]
11. Rescuing the function of mutant p53.
Bullock AN; Fersht AR
Nat Rev Cancer; 2001 Oct; 1(1):68-76. PubMed ID: 11900253
[TBL] [Abstract][Full Text] [Related]
12. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding.
Cesková P; Chichger H; Wallace M; Vojtesek B; Hupp TR
J Mol Biol; 2006 Mar; 357(2):442-56. PubMed ID: 16438982
[TBL] [Abstract][Full Text] [Related]
13. Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge.
Dehner A; Klein C; Hansen S; Müller L; Buchner J; Schwaiger M; Kessler H
Angew Chem Int Ed Engl; 2005 Aug; 44(33):5247-51. PubMed ID: 16035029
[No Abstract] [Full Text] [Related]
14. Of flies and men; p53, a tumour suppressor.
Sutcliffe JE; Brehm A
FEBS Lett; 2004 Jun; 567(1):86-91. PubMed ID: 15165898
[TBL] [Abstract][Full Text] [Related]
15. Molecular "rehabilitation" by rational drug targeting: the challenge of P53 in cancer treatment.
Tzatsos A; Papavassiliou AG
Anticancer Res; 1999; 19(5B):4353-6. PubMed ID: 10628400
[TBL] [Abstract][Full Text] [Related]
16. Hsp70 interactions with the p53 tumour suppressor protein.
Zylicz M; King FW; Wawrzynow A
EMBO J; 2001 Sep; 20(17):4634-8. PubMed ID: 11532927
[No Abstract] [Full Text] [Related]
17. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells.
Donninger H; Binder A; Bohm L; Parker MI
Biol Chem; 2008 Jan; 389(1):57-67. PubMed ID: 18095870
[TBL] [Abstract][Full Text] [Related]
18. The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity.
Okorokov AL; Sherman MB; Plisson C; Grinkevich V; Sigmundsson K; Selivanova G; Milner J; Orlova EV
EMBO J; 2006 Nov; 25(21):5191-200. PubMed ID: 17053786
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
[TBL] [Abstract][Full Text] [Related]
20. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
